The ECM-binding capacity of EBP-bFGF was detected through enzyme-linked immunosorbent assay (ELISA), and the bioactivity of EBP-bFGF was measured through the proliferative assay of human skin fibroblast cells (HSFCs), the survival of pheochromocytoma cells (PC cells) in vitro and subcutaneous embedding in vivo. The gene discussed is FGF2; the disease is pheochromocytoma.